Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trialDaniel V.T. Catenacci, Yung‐Jue Bang, Haeseong Park et al.|The Lancet Oncology|2020Cited by 190
Human cancers converge at the HIF-2α oncogenic axisAleksandra Franovic, Stephen Lee|Proceedings of the National Academy of Sciences|2009Cited by 126